Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:ARVN NASDAQ:HRMY NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.95$8.70$7.21▼$20.46$2.07B0.733.57 million shs4.37 million shsARVNArvinas$8.39$8.68$6.05▼$14.51$541.32M1.74775,676 shs643,658 shsHRMYHarmony Biosciences$37.26$32.54$25.52▼$40.87$2.16B0.94796,542 shs1.01 million shsZLABZai Lab$19.12$18.89$15.96▼$41.20$2.17B0.76899,654 shs389,048 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+2.34%+12.30%-3.56%-51.08%ARVNArvinas0.00%+4.42%+13.07%-25.22%+6.32%HRMYHarmony Biosciences0.00%+5.05%+15.71%+34.46%+16.11%ZLABZai Lab0.00%+6.22%+15.04%-6.73%-47.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.95$8.70$7.21▼$20.46$2.07B0.733.57 million shs4.37 million shsARVNArvinas$8.39$8.68$6.05▼$14.51$541.32M1.74775,676 shs643,658 shsHRMYHarmony Biosciences$37.26$32.54$25.52▼$40.87$2.16B0.94796,542 shs1.01 million shsZLABZai Lab$19.12$18.89$15.96▼$41.20$2.17B0.76899,654 shs389,048 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+2.34%+12.30%-3.56%-51.08%ARVNArvinas0.00%+4.42%+13.07%-25.22%+6.32%HRMYHarmony Biosciences0.00%+5.05%+15.71%+34.46%+16.11%ZLABZai Lab0.00%+6.22%+15.04%-6.73%-47.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.33Hold$19.67119.74% UpsideARVNArvinas 2.46Hold$15.4283.75% UpsideHRMYHarmony Biosciences 2.27Hold$41.4411.23% UpsideZLABZai Lab 2.57Moderate Buy$40.00109.21% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, HRMY, ZLAB, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026HRMYHarmony Biosciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$30.00 ➝ $36.006/26/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026HRMYHarmony Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/23/2026HRMYHarmony Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)6/18/2026ADMAADMA Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Outperform$21.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$21.006/4/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/4/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026ARVNArvinas StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$18.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$510.17M4.07$0.65 per share13.68$2.01 per share4.45ARVNArvinas$262.60M2.06N/AN/A$6.76 per share1.24HRMYHarmony Biosciences$868.45M2.48$3.18 per share11.72$15.11 per share2.47ZLABZai Lab$460.16M4.71N/AN/A$6.39 per share2.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6813.169.52N/A32.43%39.98%28.08%8/5/2026 (Estimated)ARVNArvinas-$80.80M-$3.32N/AN/AN/A-247.54%-44.38%-28.38%8/5/2026 (Estimated)HRMYHarmony Biosciences$158.69M$2.4815.029.730.3516.20%17.19%11.99%8/4/2026 (Estimated)ZLABZai Lab-$175.54M-$1.62N/AN/AN/A-39.29%-24.32%-15.52%8/6/2026 (Estimated)Latest ARVN, HRMY, ZLAB, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026ARVNArvinas-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million5/7/2026Q1 2026HRMYHarmony Biosciences$0.76$0.55-$0.21$0.55$220.84 million$215.39 million5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93ARVNArvinasN/A5.445.44HRMYHarmony Biosciences0.153.583.56ZLABZai LabN/A2.402.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%ARVNArvinas95.19%HRMYHarmony Biosciences86.23%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%ARVNArvinas7.30%HRMYHarmony Biosciences11.00%ZLABZai Lab4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableARVNArvinas42064.52 million59.81 millionOptionableHRMYHarmony Biosciences20057.89 million51.53 millionOptionableZLABZai Lab1,784113.41 million107.88 millionOptionableARVN, HRMY, ZLAB, and ADMA HeadlinesRecent News About These CompaniesZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 SharesJuly 2, 2026 | insidertrades.comZai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer TherapyJune 30, 2026 | finance.yahoo.comZai Lab (NASDAQ:ZLAB) CFO Yajing Chen Sells 2,264 Shares of StockJune 30, 2026 | americanbankingnews.comInsider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $39,529.44 in StockJune 30, 2026 | insidertrades.comZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 24,543 Shares of StockJune 30, 2026 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Stock Price Down 6.1% - Here's WhyJune 28, 2026 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares of StockJune 25, 2026 | insidertrades.comZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine CarcinomasJune 16, 2026 | finance.yahoo.comPfizer, Zai Lab win China nod for cervical cancer therapy TivdakJune 9, 2026 | msn.comZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerJune 8, 2026 | businesswire.comZai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?June 6, 2026 | finance.yahoo.comZai Lab (ZLAB) Announces Senior Leadership ChangesJune 6, 2026 | finance.yahoo.com5 Stocks That Have the Potential to Rise 1000%June 5, 2026 | insidermonkey.comZai Lab (ZLAB) Q1 2026 Earnings TranscriptJune 2, 2026 | fool.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab announces departure of president and COO Josh SmileyMay 22, 2026 | msn.comZai Lab Announces Changes to Senior Leadership TeamMay 21, 2026 | businesswire.comZai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 SharesMay 16, 2026 | insidertrades.comZai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag AttachedMay 14, 2026 | seekingalpha.comZai Lab Limited 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, HRMY, ZLAB, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$8.95 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$9.03 +0.08 (+0.86%) As of 04:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Arvinas NASDAQ:ARVN$8.39 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$8.41 +0.02 (+0.21%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Harmony Biosciences NASDAQ:HRMY$37.26 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$37.78 +0.52 (+1.40%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Zai Lab NASDAQ:ZLAB$19.12 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$19.14 +0.02 (+0.11%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
